Close Menu

sepsis

Molzym said a new analytic platform, called AutoSepT, would enable fast pathogen identification directly from specimens in less than five hours.

The firm also more than tripled its product sales year over year, and its CEO said he considered the quarter to be "transformational."

The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness. 

The deal with GeneproDx will focus on thyroid cancer, while the agreement with Endpoint Health will focus on CDx development for critical illnesses.

The company's CEO said that its single-molecule tethering technology has demonstrated limits of detection comparable to commercial molecular tests.

Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.

The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.

 

The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.

The firm reissued its full-year guidance and said it expects to sell 60 instruments in the US  for the remainder of the year.

Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.